Search Results

You are looking at 91 - 100 of 199 items for :

  • "Metastatic breast cancer" x
Clear All
Full access

Fiona Tsui-Fen Cheng, Fu Ou-Yang, Nina Lapke, Kai-Che Tung, Yen-Kung Chen, Yuh-Yu Chou and Shu-Jen Chen

–resistant metastatic breast cancer who harbor FGFR1 amplifications. Future studies are warranted to further evaluate this treatment option. Drs. Lapke, Tung, and S.J. Chen are employees of ACT Genomics. Drs. Lapke and S.J. Chen own stock in ACT Genomics

Full access

Eve Henry, Victor Villalobos, Lynn Million, Kristin C. Jensen, Robert West, Kristen Ganjoo, Alexandra Lebensohn, James M. Ford and Melinda L. Telli

( Figure 1 ). The patient received urgent radiation therapy to the right orbit to a dose of 40 Gy in 16 fractions and was started on tamoxifen and trastuzumab for presumed metastatic breast cancer. A CT-guided biopsy of the chest wall mass revealed a high

Full access

Erin Currin, Lanell M. Peterson, Erin K. Schubert, Jeanne M. Link, Kenneth A. Krohn, Robert B. Livingston, David A. Mankoff and Hannah M. Linden

patient subsequently experienced response to salvage endocrine therapy (DES). A grayscale is included for reference, with SUV for both FDG and FES. clinical diagnosis of recurrent and bone-dominant metastatic breast cancer was made 6 years from her

Full access

Richard L. Theriault

. 9 Hortobagyi GN Theriault RL Lipton A . Long-term prevention of skeletal complications of metastatic breast cancer with pamidronate. Protocol 19 Aredia Breast Cancer Study Group . J Clin Oncol 1998 ; 16 : 2038 – 2044 . 10 Libshitz

Full access

Ellen L. Jones, Lawrence B. Marks and Leonard R. Prosnitz

therapy for the treatment of recurrent cutaneous metastatic breast cancer . Cancer J Sci Am 1998 ; 4 : 378 – 384 . 38. Taber SW Fingar VH Wieman TJ . Photodynamic therapy for palliation of chest wall recurrence in patients with breast cancer

Full access

Pieter Job a MD PhD 12 2019 17 17 12 12 1512 1512 1520 1520 jnccn19021 10.6004/jnccn.2019.7326 Subdivision of M1 Stage for De Novo Metastatic Breast Cancer to Better Predict Prognosis and Response to Primary Tumor Surgery Lin Caijin MMed Wu Jiayi MD Ding

Full access

, PhD Joseph David J. a f g MBBS Galvão Daniel A. a b PhD 10 2019 17 17 10 10 1211 1211 1220 1220 jnccn18250 10.6004/jnccn.2019.7311 Guideline Discordance and Patient Cost Responsibility in Medicare Beneficiaries With Metastatic Breast Cancer Williams

Full access

Tara B. Sanft and Jamie H. Von Roenn

in patients with terminal cancer . Arch Intern Med 1988 ; 148 : 1586 – 1591 . 31 Yamamoto N Watanabe T Katsumata N . Construction and validation of a practical prognostic index for patients with metastatic breast cancer . J Clin Oncol

Full access

Pilar de la Morena Barrio, María Ángeles Vicente Conesa, Enrique González-Billalabeitia, Edgar Urrego, Elisa García-Garre, Elena García-Martínez, Marta Zafra Poves, Vicente Vicente and Francisco Ayala de la Peña

among 100,000 women in 123 randomised trials . Lancet 2012 ; 379 : 432 – 444 . 3. Ghersi D Wilcken N Simes RJ . A systematic review of taxane-containing regimens for metastatic breast cancer . Br J Cancer 2005 ; 93 : 293 – 301

Full access

Oxana Palesh, Arianna Aldridge-Gerry, Ayhan Ulusakarya, Elisabet Ortiz-Tudela, Lucile Capuron and Pasquale F. Innominato

rates declined over time, 42% of women were still experiencing insomnia symptoms at 18 months after surgery. 2 In studies of women with metastatic breast cancer, 63% have reported experiencing insomnia symptoms. 3 , 4 Insomnia also occurs in patients